{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T10:15:45Z","timestamp":1648721745444},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,10,17]],"date-time":"2015-10-17T00:00:00Z","timestamp":1445040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00120-015-3976-z","type":"journal-article","created":{"date-parts":[[2015,10,15]],"date-time":"2015-10-15T09:40:07Z","timestamp":1444902007000},"page":"381-385","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metastasiertes Nierenzellkarzinom unter Bevacizumab als Erstlinientherapie"],"prefix":"10.1007","volume":"55","author":[{"given":"R.","family":"Pichler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Horninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Heidegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,17]]},"reference":[{"key":"3976_CR1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0022-5347(17)62331-0","volume":"101","author":"Robson","year":"1969","unstructured":"Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101:297\u2013301","journal-title":"J Urol"},{"key":"3976_CR2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"Ljungberg","year":"2015","unstructured":"Ljungberg B, Bensalah K, Canfield S et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913\u2013924","journal-title":"Eur Urol"},{"key":"3976_CR3","first-page":"S0022","volume":"pii","author":"Thomas","year":"2015","unstructured":"Thomas AZ, Adibi M, Borregales LD et al (2015) Surgical management for local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy. J Urol pii: S0022-5347(15)03271-1. doi:10.1016\/j.juro.2015.02.2943","journal-title":"J Urol"},{"key":"3976_CR4","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/cncr.25836","volume":"117","author":"Alt","year":"2011","unstructured":"Alt AL, Boorjian SA, Lohse CM et al (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873\u20132882","journal-title":"Cancer"},{"key":"3976_CR5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eursup.2007.03.003","volume":"6","author":"Brinkmann","year":"2007","unstructured":"Brinkmann OA, Semik M, Gosherger G et al (2007) The role of residual tumor resection in patients with metastatic renal cell carcinoma and partial remission following immunotherapy. Eur Urol 6(Suppl):641\u2013645","journal-title":"Eur Urol"},{"key":"3976_CR6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1569-9056(10)60446-0","volume":"9","author":"Petralia","year":"2010","unstructured":"Petralia G, Roscigno M, Zigeuner R et al (2010) Complete metastasectomy is an independent predictor of cancer-specific survival in patients with clinically metastatic renal cell carcinoma. Eur Urol 9(Suppl):162","journal-title":"Eur Urol"},{"key":"3976_CR7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1569-9056(09)60246-3","volume":"8","author":"Staehler","year":"2009","unstructured":"Staehler M, Kruse J, Haseke N et al (2009) Metastasectomy significantly prolongs survival in patients with metastatic renal cancer. Eur Urol 8(Suppl):181","journal-title":"Eur Urol"},{"key":"3976_CR8","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"Escudier","year":"2007","unstructured":"Escudier B, Plszanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103\u20132111","journal-title":"Lancet"},{"key":"3976_CR9","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","volume":"28","author":"Escudier","year":"2010","unstructured":"Escudier B, Bellmunt J, N\u00e9grier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144\u20132150","journal-title":"J Clin Oncol"},{"key":"3976_CR10","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","volume":"26","author":"Rini","year":"2008","unstructured":"Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26(33):5422\u20135428","journal-title":"J Clin Oncol"},{"key":"3976_CR11","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","volume":"28","author":"Rini","year":"2010","unstructured":"Rini BI, Halabi S, Rosenberg JE et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137\u20132143","journal-title":"J Clin Oncol"},{"key":"3976_CR12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1634\/theoncologist.2012-0339","volume":"18","author":"Hurwitz","year":"2013","unstructured":"Hurwitz HI, Douglas PS, Middleton JP et al (2013) Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 18(3):273\u2013280","journal-title":"Oncologist"},{"key":"3976_CR13","doi-asserted-by":"crossref","first-page":"e0116527","DOI":"10.1371\/journal.pone.0116527","volume":"10","author":"Feliu","year":"2015","unstructured":"Feliu J, Salud A, Safont MJ et al (2015) Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS One 10(1):e0116527","journal-title":"PLoS One"},{"key":"3976_CR14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","volume":"13","author":"Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE II et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253\u20131259","journal-title":"Clin Cancer Res"},{"key":"3976_CR15","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/annonc\/mdt228","volume":"24","author":"Melichar","year":"2013","unstructured":"Melichar B, Bracarda S, Matveev V, BEVLiN Investigators et al (2013) A multinational phase II trial of bevacizumab with low-dose interferon-\u03b12a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann Oncol 24(9):2396\u20132402","journal-title":"Ann Oncol"},{"key":"3976_CR16","first-page":"mdv170","volume":"pii","author":"Ravaud","year":"2015","unstructured":"Ravaud A, Barrios CH, Alekseev B et al (2015) RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon alfa-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol pii: mdv170 (Epub ahead of print)","journal-title":"Ann Oncol"},{"key":"3976_CR17","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1158\/1078-0432.CCR-050006","volume":"10","author":"Yang","year":"2004","unstructured":"Yang JC (2004) Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 10(18 Pt 2):6367\u201363670","journal-title":"Clin Cancer Res"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-015-3976-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-015-3976-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-015-3976-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T11:48:54Z","timestamp":1567252134000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-015-3976-z"}},"subtitle":["Progressionsfreies \u00dcberleben seit 3 Jahren"],"short-title":[],"issued":{"date-parts":[[2015,10,17]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["3976"],"URL":"https:\/\/doi.org\/10.1007\/s00120-015-3976-z","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,17]]}}}